This effect is particularly apparent with presence of the BRAF mutation in a non-MSI background [4–6, 14, 79, 80, 102–104], and the significantly poorer survival rates of BRAF mutant/MSS cancers compared to other colorectal cancer subtypes are often maintained after multivariable-adjusted analyses [5, 6, 102, 104]. This evidence concerns the gene BRAF and colorectal cancer.